Investment
Features
FeesSafety
Academy
More
Pluang+

Strive may issue new preferred shares if Bitcoin price rises, benefiting both common and preferred stockholders.

Market News
29 Jul 2026
Crypto Briefing
View Source
Neutral
pluang ai news

Strive CEO Matt Cole indicated the company might raise more capital through a new preferred equity offering if Bitcoin's price continues to climb. Strive, which holds about 20,000 BTC, uses its preferred stock (SATA) to finance Bitcoin purchases, offering a 13% variable dividend paid daily to improve liquidity. While this strategy could benefit both common (ASST) and preferred shareholders, it carries risks if Bitcoin's price falls, as preferred dividends remain an obligation. Investors should watch how this approach performs in different market conditions.

More News

YMCA and Edmonton Oilers Foundation expand summer camp for 1500 kids in downtown Edmonton

YMCA and Edmonton Oilers Foundation expand summer camp for 1500 kids in downtown Edmonton

The YMCA of Northern Alberta and the Edmonton Oilers Community Foundation are partnering for the second year to offer a summer day camp experience at the Fan Park in downtown Edmonton. This year, the program has doubled its reach to nearly 1500 child...

Others
Neutral
36 minutes ago
Pearson crowns winners of 2026 Microsoft Office Specialist World Championship, showcasing top global digital skills.

Pearson crowns winners of 2026 Microsoft Office Specialist World Championship, showcasing top global digital skills.

Pearson announced the winners of the 2026 Microsoft Office Specialist World Championship held in Anaheim, California, featuring 135 finalists from 36 countries. The competition recognizes students aged 13-22 who excel in Microsoft Word, Excel, and Po...

Others
Bullish
44 minutes ago
Onco360 named national pharmacy partner for Rigel's new breast cancer drug VEPPANU

Onco360 named national pharmacy partner for Rigel's new breast cancer drug VEPPANU

Onco360, a leading independent specialty pharmacy, has been selected as a national pharmacy partner for VEPPANU (vepdegestrant), a new FDA-approved treatment for advanced or metastatic ER-positive, HER2-negative breast cancer with ESR1 mutation. VEPP...

Market News
Bullish
52 minutes ago
Raymond James raises Flex price target to $170 after strong Q1 earnings and AI-focused spin-off plan.

Raymond James raises Flex price target to $170 after strong Q1 earnings and AI-focused spin-off plan.

Raymond James upgraded Flex's price target from $150 to $170 following the company's strong fiscal Q1 2027 results, which included $7.93 billion in revenue and $1.00 adjusted earnings per share, beating estimates. Flex's Cloud and Power Infrastructur...

Analyst Insights
Bullish
1 hour ago
Airbus reports strong earnings and revenue growth, boosting aerospace sector confidence.

Airbus reports strong earnings and revenue growth, boosting aerospace sector confidence.

Airbus exceeded expectations with earnings per share of $0.59 and revenue of $23.36 billion, driven by a 54% rise in adjusted EBIT and increased aircraft deliveries. The company successfully converted its large order backlog into earnings, with a 15%...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App